• Q4 FY25 US sales up 100% to 44 units
• Total Contract Value reached a record A$6.3m, up 29% vs Q3 FY25
• Qualified for Tranche 2 of US$15m growth capital facility with SWK Funding

ImpediMed Limited (ASX: IPD) has announced a significant increase in US sales in Q4 FY25, with 44 units sold, an increase of 22 units (100%) compared to Q3 FY25 and 21 units (91%) compared to Q4 FY24. Together with quarterly renewals, the Total Contract Value for Q4 FY25 reached a record A$6.3 million, up 29% compared to A$4.9 million in Q3 FY25. This represents the highest ever quarterly TCV recorded by the company. The strong sales performance has been driven by increased leads and opportunities resulting from initiatives implemented under the new leadership team. ImpediMed is working towards achieving a similar level of sales in Q1 FY26, with improvement in subsequent quarters as the pipeline matures and additional internal initiatives take effect. Included in the Q4 FY25 sales was a 9-unit contract with Legacy Health, a six-hospital health system serving the Portland, Oregon and Vancouver, Washington metro areas. Legacy Health is implementing a lymphoedema prevention program using ImpediMed's SOZO Digital Health Platform as part of its comprehensive cancer survivorship strategy. The company also announced that it has met the prescribed FY25 sales targets and has elected to exercise the option to draw down the Tranche 2 funds of US$5 million under its US$15 million growth capital debt facility with SWK Funding LLC. This will provide ImpediMed with additional funding flexibility to support its growth and commercialisation activities.

ImpediMed is working towards achieving a similar level of sales in Q1 FY26, with improvement in subsequent quarters as the pipeline matures and additional internal initiatives take effect.

The company remains focused on executing its business plan and has built a strong pipeline that it is starting to convert. ImpediMed expects to continue seeing improving results for the coming financial year.